Truist Financial’s Definium Therapeutics DFTX Stock Holding History

Truist Financial’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-765	Closed	-$26K	–	2809
2021 Q3	$26K	Hold	765	–	–	﹤0.01%	2679
2021 Q2	$40K	Buy	+765	New	+$40.2K	﹤0.01%	2682

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Truist Financial's DFTX Position: Q4 2021 in Review

Truist Financial sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 765 shares — an estimated $26K sold.

Truist Financial first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $40K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

Truist Financial reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
Truist Financial sold 765 Definium Therapeutics shares in Q4 2021, an estimated $26K.
Truist Financial first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
Truist Financial's Definium Therapeutics position peaked at $40K in Q2 2021.
176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.